# Corsera Health: Phase 1 study in Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL (108 participants)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Corsera Health |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers |
| NCT ID | NCT07858019 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL |
| Intervention types | drug |
| Target enrollment | 108 |
| Site countries | Australia, New Zealand |
| Posted | 2026-10-05 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-05 |

## Why this score
- Industry sponsor (buys outsourced services).
- 108 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07858019). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.